Cockayne Syndrome Type 2
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Cockayne Syndrome Type 2

What is the definition of Cockayne Syndrome Type 2?
Cockayne syndrome is a rare disease which causes short stature, premature aging (progeria), severe photosensitivity, and moderate to severe learning delay. This syndrome also includes failure to thrive in the newborn, very small head (microcephaly), and impaired nervous system development. Other symptoms may include hearing loss, tooth decay, vision problems, and bone abnormalities. Inheritance is autosomal recessive. Those with type 3 live into middle adulthood.
What are the alternative names for Cockayne Syndrome Type 2?
  • Cockayne syndrome type II
  • Cockayne syndrome type 2
  • Cockayne syndrome type 2
  • Cockayne syndrome type B
Who are the top Cockayne Syndrome Type 2 Local Doctors?
Elite in Cockayne Syndrome Type 2
Elite in Cockayne Syndrome Type 2
Referral may be required
Strasbourg, FR 

Nadege Calmels practices practicing medicine in Strasbourg, France. Ms. Calmels is rated as an Elite expert by MediFind in the treatment of Cockayne Syndrome Type 2. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Cockayne Syndrome, Cockayne Syndrome Type 1, Cockayne Syndrome Type 2, and Pena-Shokeir Syndrome Type 2.

Experienced in Cockayne Syndrome Type 2
Experienced in Cockayne Syndrome Type 2
Referral may be required

Indian River Health Services Inc

3555 10th Ct, Suite 200a, 
Vero Beach, FL 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jonathan Braue is a Dermatologist practicing medicine in Vero Beach, Florida. Dr. Braue is rated as an Experienced provider by MediFind in the treatment of Cockayne Syndrome Type 2. He is also highly rated in 56 other conditions, according to our data. His clinical expertise encompasses Sunburn, Actinic Keratosis, Warts, and Seborrheic Keratosis. Dr. Braue is board certified in American Board Of Dermatology, 2019. Dr. Braue is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Cockayne Syndrome Type 2
Family Medicine
Experienced in Cockayne Syndrome Type 2
Family Medicine

Reading Hospital

420 South 5th Avenue, 
West Reading, PA 
Languages Spoken:
English
Accepting New Patients

Alan Chelius is a primary care provider, practicing in Family Medicine in West Reading, Pennsylvania. Dr. Chelius is rated as an Experienced provider by MediFind in the treatment of Cockayne Syndrome Type 2. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, and Infant Hyperglycemia. Dr. Chelius is board certified in American Board Of Family Medicine. Dr. Chelius is currently accepting new patients.

What are the latest Cockayne Syndrome Type 2 Clinical Trials?
The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

Summary: The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Coordination of Rare Diseases at Sanford

Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center